TITLE

Degludec, a New Ultralong- acting Basal Insulin for Diabetes

PUB. DATE
July 2012
SOURCE
Clinical Oncology Alert;Jul2012 Clinical Briefs, p13
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports a study by AJ Garber and colleagues which revealed that type 2 diabetic patients on degludec insulin, a recently submitted drug for FDA approval, had 20 percent fewer hypoglycemic episodes than glargine, indicating that its approval may provide a superior hypoglycemia risk.
ACCESSION #
77565923

 

Related Articles

  • HbaIc featured in diabetes diagnosis.  // Clinical Advisor;Jun2012, Vol. 15 Issue 6, p16 

    The article discusses how marked increases in hemoglobin HbaIc were shown to predict the development of diabetes. It discusses a study by Hirohito Sone and colleagues, which revealed that among the 193 participants who developed diabetes, mean HbaIc levels were higher than 5.6 percent each year...

  • Degludec, a New Ultra-long-acting Basal Insulin for Diabetes. Kuritzky, Louis // Hospital Medicine Alert;Jul2012 Clinical Briefs in Primary, p13 

    The article reports a study by AJ Garber and colleagues which revealed that type 2 diabetic patients on degludec insulin, a recently submitted drug for FDA approval, had 20 percent fewer hypoglycemic episodes than glargine, indicating that its approval may provide a superior hypoglycemia risk.

  • Degludec, a New Ultralong-acting Basal Insulin for Diabetes. Kuritzky, Louis // Clinical Cardiology Alert;7/1/2012, p13 

    The article reports a study by AJ Garber and colleagues which revealed that type 2 diabetic patients on degludec insulin, a recently submitted drug for FDA approval, had 20 percent fewer hypoglycemic episodes than glargine, indicating that its approval may provide a superior hypoglycemia risk.

  • Dipeptidyl peptidase-4 inhibitor in a patient with end-stage renal disease and type 2 diabetes. Mee Onn Chai; Noble-Bell, Georgia // Journal of Renal Nursing;Jul2015, Vol. 7 Issue 4, p180 

    No abstract available.

  • Degludec, a New Ultralong-acting Basal Insulin for Diabetes.  // Critical Care Alert;Jul2012 Clinical Briefs in, p1 

    The article reports a study by AJ Garber and colleagues which revealed that type 2 diabetic patients on degludec insulin, a recently submitted drug for FDA approval, had 20 percent fewer hypoglycemic episodes than glargine, indicating that its approval may provide a superior hypoglycemia risk.

  • FPG and HbA1c similarly predict incident diabetes.  // Diabetes Digest;2011, Vol. 10 Issue 4, p207 

    The article discusses the study of the predictive values of fasting plasma glucose (FPG) and HbA1c for prediction of type 2 diabetes (T2D).

  • HOW MUCH INSULIN DOES IT TAKE TO LOWER BLOOD SUGAR? Pereira, Kathy // Clinical Advisor;Aug2012, Vol. 15 Issue 8, p43 

    The article provides an answer to a question of how much insulin can a newly diagnozed patient with hemoglobin (Hb) A1c of 12.2 percent and glucose 350 mg/dL take despite increasing insulin (glargine [Lantus]) to 25 units.

  • Avoiding Overbasalization: The Importance of Intensifying Patients With Prandial Insulin to Achieve Proper Glycemic Control.  // Clinical Advisor;Jun2011, Vol. 14 Issue 6, p21 

    The article focuses on overbasalization and the significance of intensifiying basal insulin therapy among patients with type 2 diabetes mellitus (T2DM) to achieve adequate glycemic control. It says that increasing postprandial glucose levels and fasting add to overall hyperglycemia. It discusses...

  • The effects of education with printed material on glycemic control in patients with diabetes type 2 treated with different therapeutic regimens. Selea, Anujka; Šumarac-Dumanović, Mirjana; Pešić, Milica; Šuluburić, Dušica; Stamenković-Pejković, Danica; Cvijović, Goran; Micić, Dragan // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Aug2011, Vol. 68 Issue 8, p676 

    Background/Aim. Diabetes mellitus (DM) is considered to be an epidemic, chronic and progressive disease. The treatment of DM reqiures substantial effort from both the diabetes treatment team and a patient. Patient education is one of the treatment elements. The most efficacious form and content...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics